Filtered By:
Source: Neurology
Education: Academies
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 38 results found since Jan 2013.
Rate of Peri-Hematomal Edema Expansion Predicts Outcome after Intracerebral Hemorrhage (S39.005)
CONCLUSIONS: PHE expansion rate predicts outcome in ICH and may represent a novel therapeutic target. Study Supported by: NIH-K12-NS049453 (LB); NINDS K23NS076597 (WTK); Leon Rosenberg, MD Medical Student Research Fund in Genetics, Yale School of Medicine; 2014 Student Scholarship in Cerebrovascular Disease and Stroke, AHA Stroke Council (SU)Disclosure: Dr. Urday has nothing to disclose. Dr. Beslow has nothing to disclose. Dr. Goldstein has nothing to disclose. Dr. Dai has nothing to disclose. Dr. Zhang has nothing to disclose. Dr. Vashkevich has received research support from the National Institutes of Health. Dr. Ayres h...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Urday, S., Beslow, L., Goldstein, D., Dai, F., Zhang, F., Vashkevich, A., Ayres, A., Battey, T., Simard, M., Rosand, J., Kimberly, W., Sheth, K. Tags: Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage Source Type: research
Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Source: Neurology - September 22, 2014 Category: Neurology Authors: Culebras, A., Messe, S. R. Tags: WRITECLICK & amp;reg; EDITOR ' S CHOICE Source Type: research
HAT Score Outperforms 7 Other Hemorrhagic Transformation Scores in Ischemic Stroke Patients Treated with Thrombolysis (P3.109)
Conclusions: HAT score yielded the highest odds ratio among the 4 scores that accurately predicted sICH in our independent dataset. HAT score also had low computational complexity compared to other scores. Our results demonstrate the potential utility of the HAT score as a predictor of adverse clinical outcome for acute ischemic stroke patients undergoing IV thrombolytic therapy.Disclosure: Dr. Asuzu has nothing to disclose. Dr. Nystrom has nothing to disclose. Dr. Halliday has nothing to disclose. Dr. Wira has nothing to disclose. Dr. Greer has nothing to disclose. Dr. Schindler has nothing to disclose. Dr. Sheth has rece...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Asuzu, D., Nystrom, K., Halliday, J., Wira, C., Greer, D., Schindler, J., Sheth, K. Tags: Cerebrovascular Disease and Interventional Neurology: t-PA Source Type: research
Helping Haiti: Addressing the Burden of Neurologic Disease (P4.292)
CONCLUSIONS: With this nationwide collaborative and interdisciplinary approach, we hope to have a dramatic impact on the perceptions and outcomes of neurologic disease and provide a continuous, but dynamic presence in Port au Prince, Haiti while training physicians, nurses, and other team members in global health perspectives.Disclosure: Dr. Santini has nothing to disclose. Dr. Alessi has received personal compensation for activities with CBS Radio, the National Football League Players Association, and Colonial Cooperative Care. Dr. Jones has nothing to disclose. Dr. Etienne has nothing to disclose. Dr. Hohler has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Santini, V., Alessi, A., Jones, E., Etienne, M., Hohler, A. Tags: Global Health and Infection Source Type: research
The BioFIND Study (Fox Investigation For New Discovery Of Biomarkers In Parkinson's Disease): Design And Methodology (P4.043)
CONCLUSIONS:The BioFIND study will provide a valuable biospecimen resource for the discovery and validation of novel biomarkers in typical, moderate to advanced PD. Promising markers can then be verified in longitudinal cohorts and more heterogeneous PD subjects.Study Supported by:This study is sponsored by MJFF with support from NINDS. We also thank supports from NIH CTSA (RNA).Disclosure: Dr. Kang has received personal compensation for activities with Caremark Inc. as a medical advisory board member. Dr. Kang has received research support from Allergan, Inc. Dr. Alcalay has received personal compensation for activities w...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Kang, U., Alcalay, R., Goldman, J., Henchcliffe, C., Hogarth, P., Tuite, P., Xie, T., Frasier, M., Kopil, C., Vincent, L., Willis, N., Casaceli, C., Rudolph, A. Tags: Movement Disorders: Parkinson ' s Disease Biomarkers Source Type: research
Helping Haiti: Addressing the Burden of Neurologic Disease (I10-2.004)
CONCLUSIONS: With this nationwide collaborative and interdisciplinary approach, we hope to have a dramatic impact on the perceptions and outcomes of neurologic disease and provide a continuous, but dynamic presence in Port au Prince, Haiti while training physicians, nurses, and other team members in global health perspectives.Disclosure: Dr. Santini has nothing to disclose. Dr. Alessi has received personal compensation for activities with CBS Radio, the National Football League Players Association, and Colonial Cooperative Care. Dr. Jones has nothing to disclose. Dr. Etienne has nothing to disclose. Dr. Hohler has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Santini, V., Alessi, A., Jones, E., Etienne, M., Hohler, A. Tags: The Global Burden of Neurological Diseases Data Blitz Presentations Source Type: research
The Discharge Modified Rankin Scale Score Correlates with Established Hemorrhagic Transformation Scores in Ischemic Stroke Patients Treated with Thrombolysis (P7.118)
Conclusions: Discharge MRS scores showed robust agreement with at least 3 HT scores known to predict long-term functional outcomes after IV rt-PA therapy. Therefore, readily available discharge MRS scores may be useful indicator of patients requiring closer follow-up after IV rt-PA therapy.Disclosure: Dr. Asuzu has nothing to disclose. Dr. Nystrom has nothing to disclose. Dr. Halliday has nothing to disclose. Dr. Wira has nothing to disclose. Dr. Greer has nothing to disclose. Dr. Pritchard has nothing to disclose. Dr. Schindler has nothing to disclose. Dr. Sheth has received research support from the American Academy of N...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Asuzu, D., Nystrom, K., Halliday, J., Wira, C., Greer, D., Pritchard, D., Schindler, J., Sheth, K. Tags: Cerebrovascular Disease and Interventional Neurology: Issues in Acute Stroke Treatment Source Type: research
Identifying Novel Biomarkers of Cerebral Ischemia through the Use of Mass Spectroscopy (S15.004)
CONCLUSIONS: Mass spectroscopy-based proteomics is a potential new tool to help identify biomarkers for cerebral ischemia. Ultimately, a panel of proteins may serve as a marker for cerebral ischemia or TIA. We have identified three candidate proteins as possible indicators for cerebral ischemia. Larger studies are needed to confirm our results. Study Supported by: Stanford Cardiovascular Institute; American Brain Foundation and American Academy of Neurology Clinical Research Training FellowshipDisclosure: Dr. George has nothing to disclose. Dr. Adams has nothing to disclose. Dr. Mlynash has nothing to disclose. Dr. Kjaerga...
Source: Neurology - April 9, 2014 Category: Neurology Authors: George, P., Adams, C., Mlynash, M., Kjaergaard, C., Kuo, C., Kemp, S., Garcia, M., Albers, G., Olivot, J.-M. Tags: Cerebrovascular Disease and Interventional Neurology: Clinical and Imaging Biomarkers and Genetics Source Type: research
Carotid Artery Stenosis And Randomized Controlled Trials - Should We Abandon The Gold Standard (P7.170)
Conclusion:Explicit and unbiased application of Bayesian logic to the question of CEA vs. CAS for carotid stenosis suggests that CEA is clearly superior to CAS, and that further RCTs are very unlikely to alter this conviction. As we will demonstrate, many other contentious therapeutic questions can be profitably analyzed by this method.Disclosure: Dr. Patel has nothing to disclose. Dr. Gronseth has received personal compensation for activities with the American Academy of Neurology. Dr. Gronseth has received personal compensation in an editorial capacity for Neurology. Dr. Glantz has received personal compensation for acti...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Patel, A., Gronseth, G., Glantz, M. Tags: Cerebrovascular Disease and Interventional Neurology: Carotid Disease Source Type: research
Amyotrophic Lateral Sclerosis Quality Measures (S46.006)
CONCLUSIONS: The AAN ALS quality measures, when implemented by providers, have the potential to significantly improve care for individuals with ALS.Study Supported by:Disclosure: Dr. Miller has received personal compensation for activities with Celgene, Pharmacyclic, Teva Neuroscience, and Taiji. Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Brooks has received research support from Biogen Idec, Avanir Pharmaceuticals, Cytokinetics, Neuraltus Pharmaceutica...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Miller, R., Brooks, B., Swain-Eng, R., Basner, R., Carter, G., Casey, P., Cohen, A., Dubinsky, R., Forshew, D., Jackson, C., Kasarskis, E., Procaccini, N., Sanjak, M., Tolin, F. Tags: Neuromuscular Disease: Genetics, Pathogenesis, and Measures Source Type: research
Cerebral Amyloid Angiopathy Related Inflammation: Case Reports and Imaging Pitfalls (P2.105)
CONCLUSIONS:CAA-I can be identified by characteristic MRI findings, and evidence of microbleeds in the presence of inflammation is supportive of the diagnosis in the right clinical picture. Both cases were clinically consistent with CAA-I, presenting with subacute cognitive changes. Commonly available imaging techniques such as gradient echo -T2* may not be sensitive enough to reliably make the diagnosis. Our first case reveals that SWI was needed to make the diagnosis of CAA-I. The sensitivity of different imaging sequences should be weighed when considering the diagnosis, particularly as this affects both prognosis and t...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mcallister, M., Armstrong, M. Tags: Cerebrovascular Disease and Interventional Neurology: Acquired and Congenital Vascular Malformations Source Type: research
Randomized Controlled Trial Of Constraint-Induced Aphasia Therapy In Patients With Chronic Stroke (S21.001)
Conclusions: Overall, this randomized controlled trial did not show improvement in language abilities in this small group of subjects with chronic post-stroke aphasia receiving CIAT when compared to observation.Disclosure: Dr. Szaflarski has received personal compensation for activities with UCB Pharma. Dr. Szaflarski has received research support from the National Institutes of Health, the American Academy of Neurology, the Shor Foundation for Epilepsy Research, Neuren, and Eisai Inc. Dr. Allendorfer has received research support from the Shor Foundation for Epilepsy Research. Dr. Ball has nothing to disclose. Dr. Banks h...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Szaflarski, J., Allendorfer, J., Ball, A., Banks, C., Dietz, A., Hart, K., Lindsell, C., Martin, A., Vannest, J. Tags: Neuro-rehabilitation and Neural Repair Source Type: research
